2025 annual financial data

Inhibrx Biosciences 2025 Financial results

Direct answer

Revenue was 1,300,000 USD.

Operating income was -135,025,000 USD and net income was -140,055,000 USD.
Operating cash flow was -129,794,000 USD.

Get free Inhibrx Biosciences email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
1,300,000 USD
Operating income
-135,025,000 USD
Net income
-140,055,000 USD
Operating cash flow
-129,794,000 USD